| Identification | Back Directory | [Name]
1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE | [CAS]
145645-62-1 | [Synonyms]
NO-711
NNC 711
NNC711,HCl
NO-711 HYDROCHLORIDE
NNC-711 hydrochloride
YZYRTEYMUTWJPL-UHFFFAOYSA-N
NO-711 HCL POTENT GABA UPTAKE IN
1,2,5,6-Tetrahydro-1-(2-(((diphenylmethylene)amino)oxy]ethyl)-3-pyridinecarboxylicacidhydrochloride
1,2,5,6-TETRAHYDRO-1-[2-[[(DIPHENYLMETHYLENE)AMINO]OXY]ETHYL]-3-PYRIDINECARBOXYLIC ACID HYDROCHLORIDE
1-[2-[[(diphenylmethylene)imino]oxy]ethyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid hydrochloride
1-(2-(((DIPHENYLMETHYLENE)IMINO)OXY)ETHYL)-1,2,5,6-TETRAHYDRO-3-PYRIDINE CARBOXYLIC ACID HYDROCHLORIDE
1-[2-[[(Diphenylmethylene)imino]oxy]ethyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid hydrochloride hydrochloride | [Molecular Formula]
C21H23ClN2O3 | [MDL Number]
MFCD00153853 | [MOL File]
145645-62-1.mol | [Molecular Weight]
386.87 |
| Chemical Properties | Back Directory | [storage temp. ]
protect from light | [solubility ]
H2O: ≥10 mg/mL at 60 °C | [form ]
solid | [color ]
off-white | [Water Solubility ]
H2O: 10mg/mL at60°C | [InChI]
1S/C21H22N2O3.ClH/c24-21(25)19-12-7-13-23(16-19)14-15-26-22-20(17-8-3-1-4-9-17)18-10-5-2-6-11-18;/h1-6,8-12H,7,13-16H2,(H,24,25);1H | [InChIKey]
YZYRTEYMUTWJPL-UHFFFAOYSA-N | [SMILES]
Cl[H].OC(=O)C1=CCCN(CCO\N=C(/c2ccccc2)c3ccccc3)C1 |
| Hazard Information | Back Directory | [Uses]
NNC 711 is an anticonvulsant agent and a selective GABA uptake inhibitor (1,2). | [Uses]
NO-711 hydrochloride is suitable for use as γ-aminobutyric acid (GABA) transporter-1 (GAT-1) antagonists or GABA uptake inhibitor. | [Biological Activity]
Potent and selective inhibitor of GABA uptake by GAT-1 (IC 50 values are 0.04, 171, 1700 and 622 μ M for hGAT-1, rGAT-2, hGAT-3 and hBGT-1 respectively). Anticonvulsant following systemic administration in vivo . | [Biochem/physiol Actions]
NO-711 is a potent and selective GABA uptake inhibitor that crosses the blood-brain barrier. | [in vivo]
NNC-711 (0.25-3 mg/kg; i.p.; 30 min prior to training) prevents amnesia for a passive avoidance task induced by the acetylcholine receptor antagonist Scopolamine (HY-N0296) in male Wistar rat[2].
NNC-711 (0.5-3 mg/kg; i.p.; immediately prior to occlusion) protects against ischemia-induced death of CA1 pyramidal neurons in a model of bilateral common carotid artery occlusion in the gerbil[2].
NNC-711 (0.5-1.5 mg/kg; i.p.; immediately prior to training) exhibits significant cognition-enhancing actions in postnatal day 80 male and 28-month old female Wistar rats[2].
NNC-711 (NO-711) (50-200 μg/10 μL; i.t.; once) effectively develops analgesic effect in sciatic nerve CCI rats modelc[3].
NNC-711 (0.3-30 mg/kg, i.p.; 30 min before testing) exhibits anticonvulsant effects in Multiple mices and rats epilepsy model[4].
| Animal Model: | DMCM (HY-100369A)-induced seizures in female NMRI mice (20 g), pentylenetetrazole-induced seizures in male NMRI mice and male albino Wistar SPF rats (150-200 g), Audiogenic seizures in male DBA/2 mice (8 g) [4] | | Dosage: | 0.3-30 mg/kg | | Administration: | Intraperitoneal injection (i.p.); 30 min prior to the seizure test | | Result: | Inhibited DMCM-induced clonic seizures in NMRI mice with an ED50 = 1.2 mg/kg. |
| Animal Model: | Postnatal day 80 male Wistar rats (300-350 g)[2] | | Dosage: | 0.25, 0.5, 1, 3 mg/kg | | Administration: | Intraperitoneal injection (i.p.); 30 min prior to training | | Result: | Significantly reversed the amnesia induced by scopolamine administration 6-h post-training when retrieval was tested at 24-h post-training.
Had no effect on learning in the 0.25-0.5 mg/kg dose range, and induced amnesia at 3.0 mg/kg.
Not to directly interact with the cholinergic system, but rather to have a more general neuroprotective action on the consolidation process.
|
| Animal Model: | Postnatal day 80 male Mongolian gerbils (50-65 g)[2] | | Dosage: | 0.5, 3 mg/kg | | Administration: | Intraperitoneal injection (i.p.); immediately prior to occlusion | | Result: | Administrated immediately prior to occlusion significantly reduced CA1 cell death. |
| Animal Model: | Postnatal day 80 male Wistar rats (300-350 g) and 28-month old female Wistar rats[2] | | Dosage: | 0.5, 1.5 mg/kg | | Administration: | Intraperitoneal injection (i.p.); immediately prior to training | | Result: | Significantly reduced escape latencies in both mature postnatal day 80 and aged 28 months rats.
Improved rats ability to locate the hidden platform at 0.5 mg/kg, but the effect was reduced at 1.5 mg/kg.
Had no effect on memory retention.
|
| Animal Model: | Sciatic nerve chronic constriction injury (CCI) rats[3] | | Dosage: | 50, 100, 200 μg/10 μL | | Administration: | Intrathecal (i.t.); once | | Result: | Increased withdrawal thresholds (WT) and withdrawal latency (WL) values after 1 day compared with CCI + saline group.
The maximum value of WT was achieved 3 days after administration and maximum value of WL was achieved 1 day after administration.
|
| [storage]
Desiccate at +4°C |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|